Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC1093 | SB202190 (FHPI) |
| A highly selective, potent and cell-permeable inhibitor of p38 MAP kinase. Binds within the ATP pocket of the active kinase (Kd = 38 nM, as measured in recombinant human p38), and selectively inhibits the p38α and β isoforms (IC50 = 50 and 100 nM at SAPK2a/p38 and SAPK2b/p38β2 respectively). Promotes stability of naive human pluripotent stem cells in culture. Also available as part of the MAPK Inhibitor. | |
| BCC1096 | GW2580 |
| Potent and selective cFMS kinase inhibitor (IC50 = 0.06 μM). Exhibits selectivity for cFMS kinase over 186 other kinases. Inhibits CSF-1-induced growth of rat monocytes in vitro. Also inhibits bone resorption in osteoclast cultures, as well as connective tissue and bone destruction in a rat adjuvant arthritis model. Suppresses M-NFS-60 tumor cell growth in mice. Orally bioavailable. | |
| BCC1098 | PD98059 |
| Inhibitor of mitogen-activated protein kinase kinase (MKK / MEK). Acts by binding to the inactivated form of MEK, thereby preventing its phosphorylation by cRAF or MEK kinase (IC50 = 2-7 μM). Inhibits cell growth and proliferation in acute myelogenous leukemia (AML) cell lines; causes G1 arrest by blocking p53-dependent p21 induction. Enhances embryonic stem cell self-renewal. Also available as part of the MAPK Cascade Inhibitor and MAPK Inhibitor. | |
| BCC1099 | Celecoxib |
| Selective cyclooxygenase-2 (COX-2) inhibitor (IC50 values are 15 and 0.04 μM for COX-1 and COX-2 respectively). Anti-inflammatory with shorter plasma half-life in vivo than SC 58121. Displays chemopreventive activity in in vivo tumor models. | |
| BCC1100 | Enzastaurin (LY317615) |
| Potent PKCβ inhibitor (IC50 values are 6, 39, 83 and 110 nM for PKCβ, PKCα, PKCγ and PKCε, respectively). Suppresses proliferation and induces apoptosis in HCT116 colon carcinoma and U87MG glioblastoma cells in vitro. Reduces tumor growth and exhibits antiangiogenic activity in HT-29 colon carcinoma xenografts in mice. Also suppresses growth of HCT116 and U87MG xenografts in mice. Orally active. | |
| BCC1105 | Roscovitine (Seliciclib,CYC202) |
| Potent, selective inhibitor of cyclin-dependent kinases (cdk). Inhibits cdc2/cyclin B (IC50 = 650 nM), cdk2/cyclin A (IC50 = 700 nM), cdk2/cyclin E (IC50 = 700 nM), cdk5 / p35 (IC50 = 160 nM) and is selective over cdk4/cyclin D1 and cdk6/cyclin D3 (IC50 > 100 μM). Also selective over a wide range of related kinases including ERK1 and ERK2. Arrests L1210 cells in G1 phase. Inhibits phosphorylation of vimentin in vivo. Antimitotic. | |
| BCC1110 | KU-0060648 |
| Dual PI 3-K and DNA-PK inhibitor (IC50 values are <0.1, 0.5, 4 and 19 nM for PI 3-Kδ, PI 3-Kβ, PI 3-Kα and DNA-PK respectively). Inhibits proliferation of MCF7 cells in vitro and delays growth of MCF7 xenografts in mice. Also enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency ~2 to 4-fold, and decreases nonhomologous end-joining (NHEJ) frequency ~40%; maximum effect seen at 250 nM. | |
| BCC1114 | Mianserin HCl |
| Non-selective 5-HT2 receptor antagonist (Ki values are 0.0080 and 0.0081 μM for human 5-HT2A and 5-HT2C receptors expressed in HEK293 cells respectively). Has moderate affinity for 5-HT6. Antidepressant. | |
